PF-Atlas › Clinical Trials › NCT03119649

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

GLPG2222 50 mg · Phase 2

Registry ID
NCT03119649
Phase
Phase 2
Status
Completed
Drug / intervention
GLPG2222 50 mg
Sponsor
Lakefront Biotherapeutics NV
Start
2017-03-18
Enrollment
59
Locations
23

About this trial

This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate 4 different doses of GLPG2222 administered for 4 weeks to adult subjects with a confirmed diagnosis of CF and homozygous for the F508del Cystic Fibrosis Transmembrane conductance Regulator (CFTR) mutation.

View NCT03119649 on ClinicalTrials.gov →

Explore related

All GLPG2222 50 mg trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03119649 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.